Mineralys has been on the radar for some biotech investors. Read more about MLYS' hypertension treatment, upcoming trial ...

Medicare Part D provides coverage for Entresto. Learn more about Medicare drug coverage and the costs of Entresto.

A new study from the PARADIGM-HF and PARAGON-HF clinical trials found that sacubitril/valsartan significantly reduced the ...

The USFDA has also approved Biocon Limited subsidiary's ANDA for Daptomycin for Injection (500mg Vial) for skin infections.

Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company ...

Biocon's subsidiary, Biocon Pharma, has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Sacubitril/Valsartan tablets. This medication addresses ...

The findings presented at ESC showed that the use of sacubitril/valsartan (Sac/Val) on top of existing recommended HF therapies prompted a greater N-terminal pro-brain natriuretic peptide ...